by Richard Daverman, PhD
May 18, 2012 -- Ventac Partners has in-licensed potential diabetes 2 treatments from Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences (GIBH). The molecules target the ERR-alpha receptor, which has been shown to affect the body’s ability to respond to insulin. Ventac has placed responsibility for the venture in a new company, CASiGEN Pharma Ltd. CASiGEN will seek investors to advance development of the molecules, and it expects to form a partnership with a mainland China company to bring new diabetes drugs to the China market. More details....
